(In thousands)

Contract

Intersegment

Year Ended December 31, 2024

Therapeutics

Research

Elimination

Total

Revenue from external customers

$

16,179

$

2,541

$

—

$

18,720

Intercompany revenue

—

13,416

(13,416)

—

Cost of revenue

—

15,349

(12,557)

2,792

Bosakitug

299

—

299

ATI-2138

4,209

—

4,209

ATI-052

1,895

—

1,895

Lepzacitinib

1,300

—

1,300

Zunsemetinib

4,496

—

4,496

Discovery

5,775

—

5,775

Total Research and development project spend

17,974

—

17,974

Personnel

11,446

—

11,446

Other research and development expense⁽¹⁾

5,025

—

5,025

Total research and development

34,445

—

(859)

33,586

General and administrative

—

4,035

—

4,035

Licensing

12,666

—

12,666

Revaluation of contingent consideration

2,500

—

2,500

In-process research and development

86,905

—

86,905

Segment operating loss

$

(120,337)

$

(3,427)

$

—

$

(123,764)

Non-segment general and administrative

18,168

Other income

9,867

Loss before income taxes

(132,065)

(In thousands)

Contract

Intersegment

Year Ended December 31, 2023

Therapeutics

Research

Elimination

Total

Revenue from external customers

$

28,214

$

3,035

$

—

$

31,249

Intercompany revenue

—

16,543

(16,543)

—

Cost of revenue

—

18,960

(15,537)

3,423

Bosakitug

—

ATI-2138

12,143

—

12,143

ATI-052

—

Lepzacitinib

12,129

—

12,129

Zunsemetinib

36,461

—

36,461

Discovery

6,881

—

6,881

Total Research and development project spend

67,614

—

67,614

Personnel

18,977

—

18,977

Other research and development expense⁽¹⁾

12,799

—

12,799

Total research and development

99,390

—

(1,006)

98,384

General and administrative

—

4,561

—

4,561

Licensing

14,658

—

14,658

Revaluation of contingent consideration

(26,900)

—

(26,900)

In-process research and development

6,629

—

6,629

Segment operating loss

$

(65,563)

$

(3,943)

$

—

$

(69,506)

Non-segment general and administrative

27,851

Other income

8,509

Loss before income taxes

(88,848)

⁽¹⁾ Other segment items for the Therapeutics segment consist primarily of the following research and development expenses; stock-based compensation, depreciation and amortization, regulatory.